Neurocrine Biosciences CEO Kyle Gano Vests RSUs with Routine Tax Withholding
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filing: NEUROCRINE BIOSCIENCES INC ($NBIX) š¤ Insider: Kyle Gano (Chief Executive Officer, Director) š Transaction Date: 2026-11-01
Summary of Activity: ā¢ Acquired: 614 shares via RSU vesting ($0.00) ā¢ Withheld for Taxes (Code F): 332 shares @ $146.10 ($48,505.20 total) ā¢ Net Shares Added: 282 shares ā¢ Direct Ownership Following Transactions: 155,010 shares
Significance: Low (Routine equity award vesting and tax withholding; no discretionary open-market sales).
Comprehensive Analysis
Executive Summary
On November 3, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 for Chief Executive Officer and Director Kyle Gano. The filing reports activity that took place on November 1, 2026, consisting of the scheduled vesting of 614 Restricted Stock Units (RSUs) and the disposition of 332 shares to cover statutory tax withholding obligations.
Transaction Details
- Security: Common Stock
- RSU Conversion (Code M): 614 shares acquired at an exercise price of $0.00.
- Tax Withholding (Code F): 332 shares withheld by the issuer at $146.10 per share, amounting to an aggregate value of $48,505.20.
- Net Change in Ownership: Net increase of 282 common shares.
- Post-Transaction Holdings: 155,010 shares held directly in common stock, with 1,228 RSUs remaining under the November 1, 2024 grant.
Market and Trading Context
This filing reflects a standard, non-discretionary equity vesting event. The disposition of 332 shares was exclusively to fulfill mandatory tax obligations associated with the vest, with zero open-market sales executed. As a routine administrative transaction, it carries low trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.